Under one in 10 patients who could benefit from obesity jabs such as Wegovy can access them, warns the WHO as it releases its initial recommendations on the medications.
With in excess of 1,000,000,000 people worldwide now obese, it is urging increased and just access to GLP-1 medication.
Per estimates, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"Our new guidelines recognises that obesity is a chronic disease that can be managed with holistic and ongoing support," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and logistical bottlenecks are major hurdles to widespread availability to the treatments that can help people shift substantial weight, notes the body.
Skinny Jab Supply Crisis
Despite the current most optimistic case, the supply of GLP-1 therapies would only suffice for about 100 million people – less than 10% of eligible patients, according to the WHO.
The guideline encourages nations and manufacturers to increase availability, via strategies including patent sharing.
The intellectual property rights on the active ingredient – the core ingredient of the drug Wegovy – is scheduled to end in several countries in 2026.
The Way Obesity Injections Function
The injections imitate a biological compound to reduce digestion speed, curb appetite and increase feelings of fullness so people reduce food intake.
Individuals commonly see weight reduction in the initial weeks of commencing the regular doses.
Studies points to users may put most of the weight back on a year later of halting the medication, as their normal appetite return.
To be overweight or obese increases your risk for developing health problems, like diabetes, heart disease, stroke, and some cancers.
Excess weight concerns individuals in all nations and was responsible for over three and a half million deaths worldwide in 2024, per the health agency.
